Literature DB >> 31860136

Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.

Stephanie M Downs-Canner1, Charles E Gaber1,2, Raphael J Louie1, Paula D Strassle1,2, Kristalyn K Gallagher1, Hyman B Muss3, David W Ollila1.   

Abstract

BACKGROUND: Despite data demonstrating the safety of omitting axillary surgery in older women with early-stage breast cancer, the incidence of axillary surgery remains high. It was hypothesized that the prevalence of nodal positivity would decrease with advancing age.
METHODS: The National Cancer Data Base was used to construct a cohort of adult women with early-stage, clinically node-negative, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative breast cancer treated between 2013 and 2015. Multivariable logistic regression was used to assess the relationship between age and nodal positivity, and this was stratified by the axillary surgery category. Modified Poisson regression was used to estimate the proportion of women receiving adjuvant therapy according to age and nodal status.
RESULTS: The incidence of axillary surgery among women aged 70 and older (n = 51,917) remained high nationwide (86%). There was a significant decrease in nodal positivity with advancing age in women with early-stage, ER+, clinically node-negative breast cancer from the youngest cohort up to patients aged 70 to 89 years, and this was independent of histologic subtype (ductal vs lobular), race, comorbidities, and socioeconomic factors. Overall, less than 10% of women aged 70 or older who underwent surgery had node-positive disease, regardless of axillary surgery type, and almost 95% of node-positive patients aged 70 or older were at pathological stage N1mi or N1.
CONCLUSIONS: Axillary surgery may be safely omitted for many older women with ER+, clinically node-negative, early-stage breast cancer. Nodal positivity declines with advancing age, and this suggests varied biology in older patients versus younger patients.
© 2019 American Cancer Society.

Entities:  

Keywords:  axillary surgery; early breast cancer; geriatric oncology; hormone receptor-positive breast cancer; sentinel lymph node biopsy

Mesh:

Substances:

Year:  2019        PMID: 31860136      PMCID: PMC7369168          DOI: 10.1002/cncr.32668

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Easy SAS calculations for risk or prevalence ratios and differences.

Authors:  Donna Spiegelman; Ellen Hertzmark
Journal:  Am J Epidemiol       Date:  2005-06-29       Impact factor: 4.897

3.  Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

Authors:  Carl-Magnus Rudenstam; David Zahrieh; John F Forbes; Diana Crivellari; Stig B Holmberg; Piercarlo Rey; David Dent; Ian Campbell; Jürg Bernhard; Karen N Price; Monica Castiglione-Gertsch; Aron Goldhirsch; Richard D Gelber; Alan S Coates
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

4.  Radiation field design in the ACOSOG Z0011 (Alliance) Trial.

Authors:  Reshma Jagsi; Manjeet Chadha; Janaki Moni; Karla Ballman; Fran Laurie; Thomas A Buchholz; Armando Giuliano; Bruce G Haffty
Journal:  J Clin Oncol       Date:  2014-08-18       Impact factor: 44.544

5.  The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer.

Authors:  Ingrid G M Poodt; Robert-Jan Schipper; Guusje Vugts; Karlijn Woensdregt; Maurice van der Sangen; Adri C Voogd; Grard A P Nieuwenhuijzen
Journal:  Eur J Surg Oncol       Date:  2018-07-27       Impact factor: 4.424

6.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

7.  Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice.

Authors:  Jessemae L Welsh; Tanya L Hoskin; Courtney N Day; Elizabeth B Habermann; Matthew P Goetz; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

8.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Authors:  Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker
Journal:  BMC Med Genomics       Date:  2015-08-22       Impact factor: 3.063

9.  Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

Authors:  Daniel Herr; Manfred Wischnewsky; Ralf Joukhadar; Olivia Chow; Wolfgang Janni; Elena Leinert; Visnja Fink; Tanja Stüber; Carolin Curtaz; Rolf Kreienberg; Maria Blettner; Daniel Wollschläger; Achim Wöckel
Journal:  PLoS One       Date:  2019-07-08       Impact factor: 3.240

10.  Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

Authors:  Valentina I Petkov; Dave P Miller; Nadia Howlader; Nathan Gliner; Will Howe; Nicola Schussler; Kathleen Cronin; Frederick L Baehner; Rosemary Cress; Dennis Deapen; Sally L Glaser; Brenda Y Hernandez; Charles F Lynch; Lloyd Mueller; Ann G Schwartz; Stephen M Schwartz; Antoinette Stroup; Carol Sweeney; Thomas C Tucker; Kevin C Ward; Charles Wiggins; Xiao-Cheng Wu; Lynne Penberthy; Steven Shak
Journal:  NPJ Breast Cancer       Date:  2016-06-08
View more
  3 in total

1.  Facility-Level Variation of Low-Value Breast Cancer Treatments in Older Women with Early-Stage Breast Cancer: Analysis of a Statewide Claims Registry.

Authors:  Brooke C Bredbeck; Nicole M Mott; Ton Wang; Brandy R Sinco; Tasha M Hughes; Hari Nathan; Lesly A Dossett
Journal:  Ann Surg Oncol       Date:  2022-04-05       Impact factor: 5.344

2.  Breast cancer mortality as a function of age.

Authors:  Azadeh Nasrazadani; Juan Luis Gomez Marti; Kevin E Kip; Oscar C Marroquin; Lara Lemon; Steve D Shapiro; Adam M Brufsky
Journal:  Aging (Albany NY)       Date:  2022-02-08       Impact factor: 5.682

3.  Trends in Breast Cancer Treatment De-Implementation in Older Patients with Hormone Receptor-Positive Breast Cancer: A Mixed Methods Study.

Authors:  Ton Wang; Alison Baskin; Jacquelyn Miller; Allan Metz; Niki Matusko; Tasha Hughes; Michael Sabel; Jacqueline S Jeruss; Lesly A Dossett
Journal:  Ann Surg Oncol       Date:  2020-07-10       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.